MADRIGAL PHARMACEUTICALS, INC. Investment Income, Interest
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Investment Income, Interest of $7.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-07-30
- MADRIGAL PHARMACEUTICALS, INC. investment income, interest for the quarter ending 2026-06-30 was $7.10M, a 13.65% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. investment income, interest for the quarter ending 2026-03-31 was $8.24M, a 12.03% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. investment income, interest for the quarter ending 2025-12-31 was $9.46M, a 14.62% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. investment income, interest for the quarter ending 2025-09-30 was $10.31M, a 20.82% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. investment income, interest for fiscal 2025 was $37.36M, a 19.91% decline from fiscal 2024.
- MADRIGAL PHARMACEUTICALS, INC. investment income, interest for fiscal 2024 was $46.65M, a 138.30% increase from fiscal 2023.
- MADRIGAL PHARMACEUTICALS, INC. investment income, interest for fiscal 2023 was $19.58M, a 796.02% increase from fiscal 2022.
- MADRIGAL PHARMACEUTICALS, INC. investment income, interest for fiscal 2022 was $2.19M, a 501.93% increase from fiscal 2021.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.10M 10-Q · filed 2026-07-30 | $15.35M 10-Q · filed 2026-07-30 | $24.81M derived: sum of 3 quarters · filed 2026-07-30 | $35.11M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $8.24M 10-Q · filed 2026-05-06 | $17.70M derived: sum of 2 quarters · filed 2026-05-06 | $28.01M derived: sum of 3 quarters · filed 2026-05-06 | $36.24M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $9.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $19.77M derived: sum of 2 quarters · filed 2026-02-19 | $27.99M derived: sum of 3 quarters · filed 2026-07-30 | $37.36M 10-K · filed 2026-02-19 |
| 2025-09-30 | $10.31M 10-Q · filed 2025-11-04 | $18.54M derived: sum of 2 quarters · filed 2026-07-30 | $27.91M 10-Q · filed 2025-11-04 | $38.98M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $8.23M 10-Q · filed 2026-07-30 | $17.60M 10-Q · filed 2026-07-30 | $28.68M derived: sum of 3 quarters · filed 2026-07-30 | $41.70M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $9.37M 10-Q · filed 2026-05-06 | $20.45M derived: sum of 2 quarters · filed 2026-05-06 | $33.47M derived: sum of 3 quarters · filed 2026-05-06 | $47.69M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $11.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $24.10M derived: sum of 2 quarters · filed 2026-02-19 | $38.32M derived: sum of 3 quarters · filed 2026-02-19 | $46.65M 10-K · filed 2026-02-19 |
| 2024-09-30 | $13.02M 10-Q · filed 2025-11-04 | $27.24M derived: sum of 2 quarters · filed 2025-11-04 | $35.58M 10-Q · filed 2025-11-04 | $44.53M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $14.22M 10-Q · filed 2025-08-05 | $22.56M 10-Q · filed 2025-08-05 | $31.51M derived: sum of 3 quarters · filed 2025-08-05 | $34.81M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $8.33M 10-Q · filed 2025-05-01 | $17.29M derived: sum of 2 quarters · filed 2025-05-01 | $20.59M derived: sum of 3 quarters · filed 2025-05-01 | $24.14M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $8.95M 10-K · filed 2024-02-28 | $12.25M derived: sum of 2 quarters · filed 2024-10-31 | $15.80M derived: sum of 3 quarters · filed 2024-10-31 | $19.58M 10-K · filed 2026-02-19 |
| 2023-09-30 | $3.30M 10-Q · filed 2024-10-31 | $6.85M derived: sum of 2 quarters · filed 2024-10-31 | $10.63M 10-Q · filed 2024-10-31 | $11.70M derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | $3.55M 10-Q · filed 2024-08-07 | $7.33M 10-Q · filed 2024-08-07 | $8.40M derived: sum of 3 quarters · filed 2024-08-07 | $9.12M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $3.78M 10-Q · filed 2024-05-07 | $4.85M derived: sum of 2 quarters · filed 2024-05-07 | $5.57M derived: sum of 3 quarters · filed 2024-05-07 | $5.89M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $1.08M 10-K · filed 2024-02-28 | $1.79M derived: sum of 2 quarters · filed 2024-02-28 | $2.12M derived: sum of 3 quarters · filed 2024-02-28 | $2.19M 10-K · filed 2025-02-26 |
| 2022-09-30 | $717.00K 10-K · filed 2024-02-28 | $1.04M derived: sum of 2 quarters · filed 2024-02-28 | $1.11M derived: sum of 3 quarters · filed 2024-02-28 | |
| 2022-06-30 | $323.00K 10-K · filed 2024-02-28 | $392.00K derived: sum of 2 quarters · filed 2024-02-28 | ||
| 2022-03-31 | $69.00K 10-K · filed 2024-02-28 | |||
| 2021-12-31 | $363.00K 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |